J Ye1, H Liu, Y Hu, G Wan, J Li, Z Wang, P Li, G Zhang, Y Li. 1. Department of Otolaryngology, Head and Neck Surgery, The Third Affiliated Hospital of Sun Yat-sen University, No. 600 Tianhe Street, Guangzhou, 510630, Guangdong, China. yejin_sums@yahoo.com.cn
Abstract
PURPOSE: To explore the expression of tumoral Gal-1 in association with clinical parameters and outcome in a large population with laryngeal squamous cell carcinomas (LSCCs). METHODS: A total of 187 patients with LSCC were retrospectively enrolled. Immunohistochemistry was performed to evaluate the tumoral expression of Gal-1, apoptosis-related proteins and the density of tumor infiltrating lymphocytes (TILs) in tumor tissues before any intervene. Survival curves were estimated by the Kaplan-Meier method, and differences in survival between groups were determined using the log-rank test. Prognostic effects were evaluated by Cox regression analysis. RESULTS: A total of 102 carcinomas (54.5 %) were identified as high Gal-1 expression, and 85 carcinomas (45.5 %) as low expression. Tumoral Gal-1 expression was not significantly related with clinical stage and histology differentiation. No correlation of Gal-1 expression with apoptosis-related protein was identified. Instead, Gal-1 status was correlated positively with the ratio of FOXP3(+)/CD8(+) TILs (P = 0.024). In multivariate regression analysis, advanced clinical stage and the presence of metastases were identified as the independent predictors for poor survival in entire cohort. Especially, the statistical correlation between the Gal-1 expression and prognosis was particularly due to the late-stage tumors (P < 0.05). CONCLUSION: Current results represent valuable advancements in Gal-1 research and provided further support for using Gal-1 as a diagnostic biomarker and immunotherapeutic target for LSCC.
PURPOSE: To explore the expression of tumoral Gal-1 in association with clinical parameters and outcome in a large population with laryngeal squamous cell carcinomas (LSCCs). METHODS: A total of 187 patients with LSCC were retrospectively enrolled. Immunohistochemistry was performed to evaluate the tumoral expression of Gal-1, apoptosis-related proteins and the density of tumor infiltrating lymphocytes (TILs) in tumor tissues before any intervene. Survival curves were estimated by the Kaplan-Meier method, and differences in survival between groups were determined using the log-rank test. Prognostic effects were evaluated by Cox regression analysis. RESULTS: A total of 102 carcinomas (54.5 %) were identified as high Gal-1 expression, and 85 carcinomas (45.5 %) as low expression. Tumoral Gal-1 expression was not significantly related with clinical stage and histology differentiation. No correlation of Gal-1 expression with apoptosis-related protein was identified. Instead, Gal-1 status was correlated positively with the ratio of FOXP3(+)/CD8(+) TILs (P = 0.024). In multivariate regression analysis, advanced clinical stage and the presence of metastases were identified as the independent predictors for poor survival in entire cohort. Especially, the statistical correlation between the Gal-1 expression and prognosis was particularly due to the late-stage tumors (P < 0.05). CONCLUSION: Current results represent valuable advancements in Gal-1 research and provided further support for using Gal-1 as a diagnostic biomarker and immunotherapeutic target for LSCC.
Authors: G Choufani; N Nagy; S Saussez; H Marchant; P Bisschop; M Burchert; A Danguy; S Louryan; I Salmon; H J Gabius; R Kiss; S Hassid Journal: Cancer Date: 1999-12-01 Impact factor: 6.860
Authors: Rocio Soldati; Elisa Berger; Ana C Zenclussen; Gerhard Jorch; Holger N Lode; Mariana Salatino; Gabriel A Rabinovich; Stefan Fest Journal: Int J Cancer Date: 2011-12-05 Impact factor: 7.396
Authors: Quynh-Thu Le; Christina Kong; Phillip W Lavori; Ken O'byrne; Janine T Erler; Xin Huang; Yijun Chen; Hongbin Cao; Robert Tibshirani; Nic Denko; Amato J Giaccia; Albert C Koong Journal: Int J Radiat Oncol Biol Phys Date: 2007-09-01 Impact factor: 7.038